Evidence map›Paper›PMID 29268033›Full record

ArticleBiochemistry and cell biology = Biochimie et biologie cellulaire2018

The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration.

Dejun Yang, Joseph M Thomas, Tianxia Li, Youngseok Lee, Zhaohui Liu, Wanli W Smith

Open access · greenAbstract read
In one paragraph

Article in Biochemistry and cell biology = Biochimie et biologie cellulaire, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. JNK Pathway in CNS Pathologies.International journal of molecular sciences · 2021
    Review
  6. Article
  7. Curcumin Reduced HFrontiers in aging neuroscience · 2021
    Article
  8. G3 (Bethesda, Md.) · 2020
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Dejun Yanga Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Joseph M Thomasb Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA.
Tianxia Lib Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA.
Youngseok Leec Department of Bio and Fermentation Convergence Technology, Kookmin University, Seoul, 02707, Korea.
Zhaohui Liud Department of Human Anatomy, Soochow University School of Medicine, Suzhou, Jiangsu, 215123, China.
Wanli W Smitha Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Johns Hopkins University · USUniversity of Maryland, Baltimore · USKookmin University · KR

Funding

LRRK2, KIF5A and Parkinson diseaseR01NS093383 · NINDS · JOHNS HOPKINS UNIVERSITY · PI SMITH, WANLI W · 2016 to 2020
$2.1M
LRRK2 dimerization and therapeutic evaluationR21NS096620 · NINDS · JOHNS HOPKINS UNIVERSITY · PI SMITH, WANLI W · 2016 to 2017
$455k
NINDS NIH HHS R01 NS093383NINDS NIH HHS R21 NS096620
6 · The paper itself

Abstract

Although the pathogenesis of Parkinson's disease (PD) remains unclear, mutations in leucine-rich repeat kinase 2 (Lrrk2) are among the major causes of familial PD. Most of these mutations disrupt Lrrk2 kinase and (or) GTPase domain function, resulting in neuronal degeneration. However, the signal pathways underlying Lrrk2-induced neuronal degeneration are not fully understood. There is an expanding body of evidence that suggests a link between Lrrk2 function and MAP kinase (MAPK) cascades. To further investigate this link in vivo, genetic RNAi screens of the MAPK pathways were performed in a Drosophila model to identify genetic modifier(s) that can suppress G2019S-Lrrk2-induced PD-like phenotypes. The results revealed that the knockdown of hemipterous (hep, or JNKK) increased fly survival time, improved locomotor function, and reduced loss of dopaminergic neurons in G2019S-Lrrk2 transgenic flies. Expression of the dominant-negative allele of JNK (JNK-DN), a kinase that is downstream of hep in G2019S-Lrrk2 transgenic flies, elicited a similar effect. Moreover, treatment with the JNK inhibitor SP600125 partially reversed the G2019S-Lrrk2-induced loss of dopaminergic neurons. These results indicate that the hep pathway plays an important role in Lrrk2-linked Parkinsonism in flies. These studies provide new insights into the molecular mechanisms underlying Lrrk2-linked PD pathogenesis and aid in identifying potential therapeutic targets.

Indexed as

AnimalsAnimals, Genetically ModifiedDisease Models, AnimalDopaminergic NeuronsDrosophila melanogasterDrosophila ProteinsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MutationNeurodegenerative DiseasesProtein Serine-Threonine KinasesSignal TransductionDrosophila ProteinsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK protein, DrosophilaProtein Serine-Threonine Kinasesdégénération neuronaledopamine neuronDrosophila modelhepJNKLrrk2maladie de Parkinsonmodèle de la drosophileneuronal degenerationneurone à dopamineParkinson’s disease

Identifiers

PMID29268033
PMCPMC6441734
OpenAlexW2778533760

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.